Harpreet Singh Highlights Promise of Antibody-Drug Conjugates in Oncology
Harpreet Singh, Chief Medical Officer at Precision For Medicine, shared a post on LinkedIn:
“Antibody-drug conjugates (ADCs) are emerging as one of the most exciting modalities in oncology. By pairing targeted antibodies with potent payloads, they have the potential to bring precision and efficacy to cancers that have been historically resistant to treatment.
GSK’s SVP and Global Head of Precision Medicine, R and D, Anne-Marie Martin, PhD, recently shared in an interview, ‘Clearly, antibody-drug conjugates (ADCs) are very promising. If they are as successful as the field hopes, they will have the potential to impact a broad range of cancer types and patient populations. Combining them with conventional IO therapies will be part of future IO treatment.’
GSK’s B7-H3–targeted ADC has received multiple regulatory designations:
- FDA Breakthrough Therapy Designation for adults with relapsed or refractory osteosarcoma who have progressed after at least 2 prior lines of therapy (January)
- FDA Breakthrough Therapy Designation for relapsed/refractory extensive-stage small-cell lung cancer (December 2024)
- EMA PRIME designation (2024)
Osteosarcoma and small-cell lung cancer have long lacked new treatment options, making these designations a significant step toward innovation for patients and families who urgently need it.”
More posts featuring Harpreet Singh on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023